GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (MEX:REGN) » Definitions » Effect of Exchange Rate Changes

Regeneron Pharmaceuticals (MEX:REGN) Effect of Exchange Rate Changes : MXN8 Mil (TTM As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Regeneron Pharmaceuticals Effect of Exchange Rate Changes?

Regeneron Pharmaceuticals's Effect of Exchange Rate Changes for the three months ended in Mar. 2025 was MXN12 Mil.

Regeneron Pharmaceuticals's Effect of Exchange Rate Changes for the trailing twelve months (TTM) ended in Mar. 2025 was MXN8 Mil.

Regeneron Pharmaceuticals Effect of Exchange Rate Changes Historical Data

The historical data trend for Regeneron Pharmaceuticals's Effect of Exchange Rate Changes can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Effect of Exchange Rate Changes Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Effect of Exchange Rate Changes
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -6.79 -14.60

Regeneron Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Effect of Exchange Rate Changes Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.30 -5.50 15.75 -14.60 12.28

Regeneron Pharmaceuticals Effect of Exchange Rate Changes Calculation

Effect of Exchange Rate Changes represents the effect of exchange rate changes on cash balances held in foreign currencies.

Effect of Exchange Rate Changes for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals Effect of Exchange Rate Changes Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Effect of Exchange Rate Changes provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (MEX:REGN) » Definitions » Effect of Exchange Rate Changes
Comparable Companies
ALNY ONC BNTX SMMT RPRX INSM BMRN INCY MRNA EXEL VRTX ASX:CSL XKRX:207940 XBRU:ARGX XBRU:UCB XKRX:068270 XKRX:196170 OCSE:GMAB HKSE:02269 SHSE:603392
Traded in Other Exchanges
REGN:USA 0R2M:UK RGO:Germany REGN34:Brazil REGN:Austria
Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Website
https://www.regeneron.com
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).